Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease-Reference-Cited by-同舟云学术

Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease

Published:2001-10 Issue:9291 Volume:358 Page:1389-1399
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Publisher

Elsevier BV

Subject

General Medicine

Reference55 articles.

1. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies;Lancet,1996

2. Breast cancer and hormonal contraceptives: further results;Contraception,1996

3. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer;Lancet,1997

4. Oral contraceptives and breast cancer: final report of an epidemiologic study;Vessey;Br J Cancer,1983

5. Oral contraceptive use and breast cancer or cervical cancer: preliminary results of a French case-control study;Lê,1984

Cited by 891 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucocorticoid receptors orchestrate a convergence of host and cellular stress signals in triple negative breast cancer;The Journal of Steroid Biochemistry and Molecular Biology;2024-10

2. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024;MMWR. Recommendations and Reports;2024-08-08

3. The multifaceted role of SOX2 in breast and lung cancer dynamics;Pathology - Research and Practice;2024-08

4. Frequency of Deleterious Germline Variants in HER2-Low Breast Cancer Patients Using a Hereditary Multipanel Gene Testing;Current Issues in Molecular Biology;2024-07-25

5. In-silico Binding, Stability, Pharmacokinetics, and Toxicity Studies on Natural (-)-ambrox Metabolites as Binding Ligands to Luminal B and Triple-negative/basal-like Proteins for Breast Cancer Therapy;Letters in Drug Design & Discovery;2024-07